The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
GIP Bolus
GIP Clamp
Oral glucose tolerance test (OGTT)
hyperglycemic clamp
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide 1 (GLP-1), Incretin, Insulin secretion, Tachyphylaxis
Eligibility Criteria
Inclusion Criteria:
- Exclusion of pregnancy
- Exclusion of impaired glucose tolerance or type 2 diabetes in metabolical healthy subjects
- current diagnosis of type 2 diabetes according to the guidelines of the German Diabetes Association (DDG) ( Kerner et al . 2001) in subjects of diabetes group
- fasting glucose ≤ 150 mg/dl
- Body-mass-index ≥ 20 kg/m²
- Written consent
Exclusion Criteria:
- Type 1 diabetes
- Impaired glucose tolerance or Type 2 diabetes in metabolical healthy subjects
- Ketone bodies urine diagnostics at least ++
- Acidosis
- Fasting blood glucose > 150 mg/dl
- Body-mass-index < 20 kg/m²
- No written consent
- Pregnancy or unsafe contraception in women before menopause
- Active malignancy
- Angina as current, unsolved clinical problem
- Inadequately treated or untreated arterial hypertension ( > 160 mmHg systolic and / or > 95 mmHg diastolic )
- Infection / fever > 37.5 ° C
- Treatment with glucocorticoids
- Insulin therapy within the last three months
- Anemia with a hemoglobin level < 12 g/dl
- Liver function limitations
- Renal impairment ( serum creatinine > 1.5 mg/dl )
- Alcohol or drug abuse
- Participation in clinical trials in the last 3 months
- Inability or unwillingness to comply with the requirements of the Protocol
- Known hypersensitivity to GIP
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Oral glucose tolerance test
GIP Bolus
GIP Infusion
Arm Description
An oral glucose challenge (75 g)
Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
Outcomes
Primary Outcome Measures
Insulin secretory response after GIP bolus or infusion.
Secondary Outcome Measures
Full Information
NCT ID
NCT02673554
First Posted
January 28, 2016
Last Updated
February 1, 2016
Sponsor
Diabeteszentrum Bad Lauterberg im Harz
1. Study Identification
Unique Protocol Identification Number
NCT02673554
Brief Title
The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP
Official Title
The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of Glucose-dependent Insulinotropic Polypeptide (GIP) in Patients With Type 2 Diabetes is Not Caused by Rapid Tachyphylaxis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabeteszentrum Bad Lauterberg im Harz
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In patients with type 2 diabetes, the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) has lost its insulinotropic activity, but more so after continuous versus bolus administration. The design was a two-way crossover design comparing repeated bolus injection and continuous infusion of GIP under hyperglycaemic clamp conditions. Patients were age- gender- and weight-matched with type 2 diabetes, first degree relatives of such patients, and healthy subjects. Investigators performed a:
Oral glucose challenge;
hyperglycemic clamp (8.5 mmol/l) with two repeated GIP bolus administrations (50 pmol/kg body weight at 30 and 120 min); and
hyperglycemic clamp with continuous administration of GIP (2 pmol.kg-1.min-1 from 30-180 min).
To answer the question, whether rapid tachyphylaxis occurs with regard to the insulinotropic action of GIP, investigators studied type 2-diabetic patients, their first-degree relatives, and healthy controls under hyperglycaemic clamp conditions with two GIP bolus injections 90 min apart, and compared this to a continued intravenous infusion of GIP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide 1 (GLP-1), Incretin, Insulin secretion, Tachyphylaxis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oral glucose tolerance test
Arm Type
Experimental
Arm Description
An oral glucose challenge (75 g)
Arm Title
GIP Bolus
Arm Type
Active Comparator
Arm Description
Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
Arm Title
GIP Infusion
Arm Type
Active Comparator
Arm Description
Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
Intervention Type
Drug
Intervention Name(s)
GIP Bolus
Intervention Description
bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
Intervention Type
Drug
Intervention Name(s)
GIP Clamp
Intervention Description
hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
Intervention Type
Procedure
Intervention Name(s)
Oral glucose tolerance test (OGTT)
Intervention Description
an oral glucose challenge (75 g)
Intervention Type
Procedure
Intervention Name(s)
hyperglycemic clamp
Intervention Description
a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
Primary Outcome Measure Information:
Title
Insulin secretory response after GIP bolus or infusion.
Time Frame
210 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Exclusion of pregnancy
Exclusion of impaired glucose tolerance or type 2 diabetes in metabolical healthy subjects
current diagnosis of type 2 diabetes according to the guidelines of the German Diabetes Association (DDG) ( Kerner et al . 2001) in subjects of diabetes group
fasting glucose ≤ 150 mg/dl
Body-mass-index ≥ 20 kg/m²
Written consent
Exclusion Criteria:
Type 1 diabetes
Impaired glucose tolerance or Type 2 diabetes in metabolical healthy subjects
Ketone bodies urine diagnostics at least ++
Acidosis
Fasting blood glucose > 150 mg/dl
Body-mass-index < 20 kg/m²
No written consent
Pregnancy or unsafe contraception in women before menopause
Active malignancy
Angina as current, unsolved clinical problem
Inadequately treated or untreated arterial hypertension ( > 160 mmHg systolic and / or > 95 mmHg diastolic )
Infection / fever > 37.5 ° C
Treatment with glucocorticoids
Insulin therapy within the last three months
Anemia with a hemoglobin level < 12 g/dl
Liver function limitations
Renal impairment ( serum creatinine > 1.5 mg/dl )
Alcohol or drug abuse
Participation in clinical trials in the last 3 months
Inability or unwillingness to comply with the requirements of the Protocol
Known hypersensitivity to GIP
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael A. Nauck, Prof.
Organizational Affiliation
Diabeteszentrum Bad Lauterberg
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP
We'll reach out to this number within 24 hrs